Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
1(8%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
2
17%
Ph phase_1
9
75%

Phase Distribution

9

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
9(81.8%)
Phase 2Efficacy & side effects
2(18.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(6)
Terminated(2)
Other(3)

Detailed Status

Completed6
unknown3
Terminated1
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Phase 19 (81.8%)
Phase 22 (18.2%)

Trials by Status

unknown325%
terminated18%
withdrawn18%
completed650%
recruiting18%

Recent Activity

1 active trials
Showing 5 of 12
recruitingphase_1

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

NCT06344715
completedphase_1

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

NCT03752723
unknownphase_2

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

NCT05191784
terminatedphase_1

Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19

NCT04730427
withdrawnphase_1

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

NCT04065087
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06344715Phase 1

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Recruiting
NCT03752723Phase 1

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

Completed
NCT05191784Phase 2

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Unknown
NCT04730427Phase 1

Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19

Terminated
NCT04065087Phase 1

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Withdrawn
NCT04289155

Individual Patient Compassionate Use of GX-I7

Unknown
NCT04810637Phase 2

A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19

Unknown
NCT03619239Phase 1

Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma

Completed
NCT03733587Phase 1

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Completed
NCT03478995Phase 1

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Completed
NCT03144934Phase 1

Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

Completed
NCT02860715Phase 1

Clinical Trial of GX-I7 in Healthy Volunteers

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12